ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DNDN (MM)

0.1314
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:DNDN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1314 0 01:00:00

Dendreon Announces Webcast Presentations at Upcoming Investor Conferences

04/09/2009 10:43pm

PR Newswire (US)


(MM) (NASDAQ:DNDN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more (MM) Charts.
SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that management will present at the following four upcoming investor conferences. Rodman & Renshaw 11th Annual Health Care Conference Wednesday, September 9, 2009 4:05 p.m. ET Morgan Stanley 2009 Global Health Care Unplugged Conference Tuesday, September 15, 2009 8:35 a.m. ET BioCentury 16th Annual NewsMakers in the Biotech Industry Conference Wednesday, September 16, 2009 1:30 p.m. ET UBS 2009 Global Life Sciences Conference Wednesday, September 23, 2009 1:00 p.m. ET The presentations at Rodman & Renshaw, BioCentury NewsMakers and UBS will be audio webcast live and available for replay from Dendreon's website, http://www.dendreon.com/. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. DATASOURCE: Dendreon Corporation CONTACT: Jennifer Williams, Investor Relations of Dendreon Corporation, +1-206-829-1500 Web Site: http://www.dendreon.com/

Copyright

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart